L Harnisch
Overview
Explore the profile of L Harnisch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wilkins J, Chan P, Chard J, Smith G, Smith M, Beer M, et al.
CPT Pharmacometrics Syst Pharmacol
. 2017 May;
6(5):285-292.
PMID: 28504472
Pharmacometric analyses are complex and multifactorial. It is essential to check, track, and document the vast amounts of data and metadata that are generated during these analyses (and the relationships...
2.
Abrantes J, Nielsen E, Korth-Bradley J, Harnisch L, Jonsson S
Clin Pharmacol Ther
. 2017 Apr;
102(6):977-988.
PMID: 28437834
This study investigated the disposition of coagulation factor VIII activity in 754 patients with moderate to severe hemophilia A following the administration of moroctocog alfa, a B-domain deleted recombinant factor...
3.
Bhattacharya I, Manukyan Z, Chan P, Harnisch L, Heatherington A
Clin Pharmacol Ther
. 2016 Jun;
100(4):330-2.
PMID: 27351288
Approximately 50% of rare diseases are evident in children. Fatal disease prognosis and lack of treatments causes 30% of affected children to not live past their fifth birthday. This clear...
4.
Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O, et al.
CPT Pharmacometrics Syst Pharmacol
. 2016 Apr;
5(3):93-122.
PMID: 27069774
This document was developed to enable greater consistency in the practice, application, and documentation of Model-Informed Drug Discovery and Development (MID3) across the pharmaceutical industry. A collection of "good practice"...
5.
Swat M, Moodie S, Wimalaratne S, Kristensen N, Lavielle M, Mari A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2015 Jul;
4(6):316-9.
PMID: 26225259
The lack of a common exchange format for mathematical models in pharmacometrics has been a long-standing problem. Such a format has the potential to increase productivity and analysis quality, simplify...
6.
Harnisch L, Matthews I, Chard J, Karlsson M
CPT Pharmacometrics Syst Pharmacol
. 2013 Jul;
2:e34.
PMID: 23887647
Model-based drug development (MBDD) is accepted as a vital approach in understanding patients' drug-related benefit and risk by integrating quantitative information integration from diverse sources collected throughout drug development.(1) This...
7.
Harnisch L, Shepard T, Pons G, Pasqua O
CPT Pharmacometrics Syst Pharmacol
. 2013 Jul;
2:e28.
PMID: 23835939
The registration and approval of novel medicines have traditionally been based on evidence arising from large prospective trials. Such an approach is often not possible or unsuitable to evaluate the...
8.
Weber W, Harnisch L, Zimmer M, Rokitta C, Mendes P
Int J Clin Pharmacol Ther
. 1995 Oct;
33(10):560-4.
PMID: 8574507
The time above the minimum inhibitory concentration (MIC) is an important surrogate parameter for the efficacy of cephalosporines. In clinical practice cefotaxime (CTX) is usually administered every 8 h or...
9.
Weber W, Kewitz G, Rost K, Looby M, Nitz M, Harnisch L
Eur J Clin Pharmacol
. 1993 Jan;
44 Suppl 1:S23-5.
PMID: 8486141
A population kinetic analysis was carried out on sparse plasma gentamicin (GE) concentration data from 469 neonates obtained as part of a routine therapeutic drug monitoring (TDM) programme in the...
10.